Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
49 hedge funds and large institutions have $252M invested in Aerie Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGHSA
TPG Group Holdings (SBS) Advisors
Fort Worth,
Texas
|
+$57.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$21.6M |
| 3 |
Schroder Investment Management Group
London,
United Kingdom
|
+$5.44M |
| 4 |
BC
Broadfin Capital
New York
|
+$5.1M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$4.17M |
Top Sellers
AERI Hedge Fund Activity: Q4 2013 in Review
49 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2013, worth a combined $252M.
Buyers outnumbered sellers: 49 funds opened new AERI positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TPG Group Holdings (SBS) Advisors, opening a new position worth an estimated $57.2M.
- 49 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $252M of Aerie Pharmaceuticals stock for Q4 2013.
- 49 funds opened new Aerie Pharmaceuticals positions in Q4 2013 and 0 closed out, a net change of +49 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2013 was TPG Group Holdings (SBS) Advisors, an estimated $57.2M added.
Based on aggregated 13F filings for Q4 2013.